Adverse food-drug interactions

Regulatory Toxicology and Pharmacology

Volumn 73, Issue 3, 2015, Pages 859-865

  de Boer, Alie ^a   van Hunsel, Florence ^b   Bast, Aalt ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Netherlands Pharmacovigilance Centre Lareb   (Netherlands)

Author keywords

Adverse interactions; Bioactives; European legislation; Food law; Food supplements; Health enhancing products; Medicinal products; Wellness

Indexed keywords

ASCORBIC ACID; CHONDROITIN; CRANBERRY EXTRACT; FISH OIL; GINKGO BILOBA EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; MELATONIN; MULTIVITAMIN; PHYTOSTEROL; VALERIAN; VITAMIN B COMPLEX; XENOBIOTIC AGENT; PLANT MEDICINAL PRODUCT;

ABSORPTION; ARTICLE; BIOTRANSFORMATION; CONSUMER HEALTH INFORMATION; DIET SUPPLEMENTATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD DRUG INTERACTION; FOOD SAFETY; HUMAN; LAW; NUTRITIONAL HEALTH; PRESCRIPTION; PRIORITY JOURNAL; WELLBEING; ADVERSE EFFECTS; DIETARY SUPPLEMENT; HEALTH CARE POLICY; HERB DRUG INTERACTION; LEGISLATION AND JURISPRUDENCE; MANAGEMENT; PRODUCT SAFETY; RISK ASSESSMENT; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOTRANSFORMATION; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; HEALTH POLICY; HERB-DRUG INTERACTIONS; HUMANS; PHARMACOVIGILANCE; PLANT PREPARATIONS; POLICY MAKING; RISK ASSESSMENT; RISK FACTORS;

EID: 84952719858     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.10.009     Document Type: Article

References (50)

1. Alissa E.M. Medicinal herbs and therapeutic drugs interactions. Ther. Drug Monit. 2014, 36:413-422. 10.1097/FTD.0000000000000035.
2. Bast A., Kaiserová H., Hartog G.J.M., Haenen G.R.M.M., van der Vijgh W.J.F. Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol. Toxicol. 2006, 23:39-47. 10.1007/s10565-006-0139-4.
3. Baxter K. Stockley's Drug Interactions 2008, Pharmaceutical Press, London. eighth ed.
4. Biesalski H.-K., Dragsted L.O., Elmadfa I., Grossklaus R., Müller M., Schrenk D., Walter P., Weber P. Bioactive compounds: definition and assessment of activity. Nutrition 2009, 25:1202-1205. 10.1016/j.nut.2009.04.023.
5. Boersma H.H., Stolk L.M.L. Innemen 2 uur voor of na een menu met spruitjes". Voeding en het metabolisme van geneesmiddelen. Pharm. Weekbl. 1999, 134:1254-1259.
6. Boullata J.I., Hudson L.M. Drug-nutrient interactions: a broad view with implications for practice. J. Acad. Nutr. Diet. 2012, 112:506-517. http://dx.doi.org/10.1016/j.jada.2011.09.002.
7. Cheng T.O. Food-drug interactions. Int. J. Cardiol. 2006, 106:392-393. http://dx.doi.org/10.1016/j.ijcard.2004.12.083.
8. Chong P.-W., Lau K.-Z., Gruenwald J., Uebelhack R. A review of the efficacy and safety of litramine IQP-G-002AS, an Opuntia ficus-indica derived fiber for weight management. Evid. Based Complement. Altern. Med. 2014, 943713. 10.1155/2014/943713.
9. Commissie Farmacotherapeutisch Kompas Zorginstituut Nederland Farmacotherapeutisch Kompas [WWW Document] 2015, https://www.farmacotherapeutischkompas.nl/.
10. Council of the European Union Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Off. J. Eur. Commun. L 1993, 169(36):1-43.
11. Council of the European Union Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the member states relating to active implantable medical devices. Off. J. Eur. Commun. L 1990, 189(33):17-36.
12. Euromonitor International Fortified/Functional Packaged Food - Worldwide Historic Growth (2009-2014) 2015.
13. Euromonitor International Health and Wellness: Functionality, Naturalness and Stevia Key to Developing Beverages to Fit Today's Trends 2013.
14. Euromonitor International Female Breadwinners - How the Rise in Working Women Is Influencing Spending Patterns 2011.
15. European Food Information Council Functional Foods [WWW Document] 2015, http://www.eufic.org/article/en/expid/basics-functional-foods/.
16. European Parliament and Council of the European Union Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive(.). Off. J. Eur. Union L 2013, 181(56):35-56.
17. European Parliament and Council of the European Union Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the community code relating to medicinal products for human use. Off. J. Eur. Union L 2010, 348(53):74-99.
18. European Parliament and Council of the European Union Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down community procedures for the authorisa(.). Off. J. Eur. Union L 2010, 348(53):1-16.
19. European Parliament and Council of the European Union Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines(.). Off. J. Eur. Union L 2004, 136(47):1-33.
20. European Parliament and Council of the European Union Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the community code relating to medicinal products for human use. Off. J. Eur. Union L 2004, 136(47):34-57.
21. European Parliament and Council of the European Union Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the community code relating to medicinal products for human use. Off. J. Eur. Union L 2004, 136(47):85-90.
22. European Parliament and Council of the European Union Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food(.). Off. J. Eur. Commun. L 2002, 31(45):1-24.
23. European Parliament and Council of the European Union Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Off. J. Eur. Commun. L 2002, 183(45):51-57.
24. European Parliament and Council of the European Union Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Off. J. Eur. Commun. L 2001, 311(44):67-128.
25. European Parliament and Council of the European Union Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Off. J. Eur. Commun. L 1998, 331(41):1-37.
26. Eussen S.R.B.M., Verhagen H., Klungel O.H., Garssen J., van Loveren H., van Kranen H.J., Rompelberg C.J.M. Functional foods and dietary supplements: products at the interface between pharma and nutrition. Eur. J. Pharmacol. 2011, 668:S2-S9. http://dx.doi.org/10.1016/j.ejphar.2011.07.008.
27. Fasinu P.S., Bouic P.J., Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol. 2012, 3:69. 10.3389/fphar.2012.00069.
28. Fugh-Berman A. Herb-drug interactions. Lancet 2000, 355:134-138.
29. Georgiou N.A., Garssen J., Witkamp R.F. Pharma-nutrition interface: the gap is narrowing. Eur. J. Pharmacol. 2011, 651:1-8. http://dx.doi.org/10.1016/j.ejphar.2010.11.007.
30. Grube B., Chong P.-W., Lau K.-Z., Orzechowski H.-D. A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study. Obesity 2013, 21:58-64. 10.1002/oby.20244.
31. Harrison-Dunn A.-R. In the Eye of the Beholder: Where Does the EU Stand on Beauty Claims? [WWW Document] 2015, (accessed 4.23.15.). http://www.nutraingredients.com/Trends/Health-claims/Where-does-the-EU-stand-on-beauty-claims.
32. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 2009, 69:1777-1798.
33. Katan M.B. Health claims for functional foods: regulations vary between countries and often permit vague claims. Br. Med. J. 2004, 328:180.
34. Knudsen J.F., Sokol G.H. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy 2008, 28:540-548. 10.1592/phco.28.4.540.
35. Lachmann P.J. The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. QJM 2012, 105:1179-1189. 10.1093/qjmed/hcs148.
36. Liel Y., Harman-Boehm I., Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J. Clin. Endocrinol. Metab. 1996, 81:857-859. 10.1210/jcem.81.2.8636317.
37. McClendon K.S., Riche D.M., Uwaifo G.I. Orlistat: current status in clinical therapeutics. Expert Opin. Drug Saf. 2009, 8:727-744.
38. Menrad K. Market and marketing of functional food in Europe. J. Food Eng. 2003, 56:181-188. http://dx.doi.org/10.1016/S0260-8774(02)00247-9.
39. Netherlands Pharmacovigilance Centre Lareb Lareb - Home [WWW Document] 2015, (accessed 04.23.15.). http://www.lareb.nl/?lang=en-GB.
40. Netherlands Pharmacoviglance Centre Lareb Lareb - History [WWW Document] 2015, (accessed 04.23.15.). http://www.lareb.nl/Over-Lareb/Geschiedenis.
41. Netherlands Pharmacoviglance Centre Lareb Lareb - FAQ's [WWW Document] 2015, (accessed 04.23.15.). http://www.lareb.nl/Over-Lareb/Veel-gestelde-vragen.
42. Pirmohamed M. Drug-grapefruit juice interactions. BMJ Br. Med. J. 2013, 346. http://dx.doi.org/10.1136/bmj.f1.
43. Ruijters E.J.B., Haenen G.R.M.M., Weseler A.R., Bast A. The cocoa flavanol (-)-epicatechin protects the cortisol response. Pharmacol. Res. 2014, 79:28-33. http://dx.doi.org/10.1016/j.phrs.2013.11.004.
44. Ruijters E.J.B., Haenen G.R.M.M., Weseler A.R., Bast A. The anti-inflammatory efficacy of dexamethasone is protected by (-)-epicatechin. PharmaNutrition 2014, 2:47-52. 10.1016/j.phanu.2014.04.001.
45. Sissingh-Blok, L., n.d. Voeding & Geneesmiddelen - Weerzijdse interacties. Natura Foundation, Numansdorp.
46. Ulrich R.G. Idiosyncratic toxicity: a convergence of risk factors. Annu. Rev. Med. 2007, 58:17-34. 10.1146/annurev.med.58.072905.160823.
47. Wiegman D.-J., Brinkman K., Franssen E.J.F. Interaction of Ginkgo biloba with efavirenz. AIDS 2009, 23:1184-1185. 10.1097/QAD.0b013e32832c412b.
48. Williamson E.M., Driver S., Baxter K. Stockley's Herbal Medicines Interactions 2013, Pharmaceutical Press, London. second ed.
49. World Health Organization Pharmacovigilance [WWW Document 2015, (accessed 04.23.15.). http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/.
50. Zhang Z.-Y., Wong Y.N. Enzyme kinetics for clinically relevant CYP inhibition. Curr. Drug Metab. 2005, 6:241-257.